ENZYCHEM LIFESCIENCES CORPORATION
KOSDAQ-listed pharma-biotech developing the EC-18 drug pipeline alongside API, health-functional-food, and bio-oil businesses.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1999 and listed on KOSDAQ in 2018, Enzychem Lifesciences is a pharma-biotech company focused on global new drug development and pharmaceuticals. It is developing its drug candidate EC-18 as a treatment for chemoradiation-induced oral mucositis (CRIOM), acute radiation syndrome (ARS), and atopic dermatitis (AD), alongside active pharmaceutical ingredients such as erdosteine and gadobutrol, the health-functional food 'Rokpid Immune,' and a bio-oil business (HVO/SAF feedstock) run by its subsidiary Shinheung Co. Its current revenue mix is 33.8% from APIs and 66.2% from bio-oil, and it has registered more than 40 API products with Korea's Ministry of Food and Drug Safety, exporting to China, India, Russia, and other markets.
Products & technology
- EC-18Drug candidate for CRIOM, ARS, and atopic dermatitis
- ErdosteineExpectorant
- GadobutrolMRI contrast agent
- D-CycloserineAnti-tuberculosis agent
- SarpogrelateAnticoagulant
- Zinc CarnosineAnti-ulcer agent
- ZaltoprofenAnti-inflammatory analgesic
- Rokpid Immune / Immune VitaminIndividually-approved health functional food based on deer-antler-derived PLAG for immune modulation
Clinical trials
data.go.kr6 MFDS clinical trial authorisations · 2014–2024 (Phase 2 3 · Phase 1 2 · Phase 1/2 1)
- Phase 2EC-182024-10-30
1 trial site
- Phase 2EC-182020-05-12
5 trial sites
- Phase 2EC-182020-04-02
1 trial site
- Phase 1/2EC-182016-12-02
6 trial sites
- Phase 1EC-182015-07-21
1 trial site
- Phase 1EC-182014-06-12
1 trial site
R&D and key agreements
Source: DART corporate disclosureEC-18 · CRIOM/ARS/AD · 비임상·임상 진행중 · Mechanism-based candidate under development for multiple indications
AI 기반 혁신신약 발굴 플랫폼 및 세노테라퓨틱스 · 연구단계(2024년부터) · AI-driven drug discovery platform and senotherapeutics research since 2024
DAC(Degrader-Antibody Conjugates) · 연구 포트폴리오 편입(2025년 4분기) · Antibody-based degrader conjugate technology; expanding into ADC and PROTAC modalities
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition